Objectives The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …

In 10% of patients, who suffer an acute coronary syndrome (ACS), a major cardiovascular
event occurs despite optimal therapy. The occlusion of the vessel is driven by …

Objectives: The authors assessed the use of dual antiplatelet therapy (DAPT) and outcomes
in patients undergoing percutaneous coronary intervention (PCI) during the ROCKET AF …

Background Despite numerous randomized clinical trials (RCT), data regarding the efficacy
of antiplatelet and anticoagulant combinations are still conflicting. We aimed to analyze …

For 4 decades, antithrombotic therapy with aspirin has been a cornerstone of secondary
prevention for patients with chronic atherosclerotic cardiovascular disease (ASCVD) …

Single antiplatelet therapy (SAPT) and intensified antithrombotic regimens (prolonged dual
antiplatelet therapy [DAPT] or dual pathway inhibition [DPI]) are recommended for …

Very low–dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid
(ASA) and clopidogrel, is associated with improved outcomes in patients with acute coronary …

We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC)
treatment. A search of the medical literature was performed from inception until May 31 …

Aim After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …

Aims To describe outcomes of patients with chronic coronary artery disease (CAD) and/or
peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using …